Update on current approaches to diagnosis and treatment of onychomycosis

被引:41
作者
Gupta, Aditya K. [1 ,2 ]
Mays, Rachel R. [1 ]
Versteeg, Sarah G. [1 ]
Shear, Neil H. [2 ,3 ]
Piguet, Vincent [2 ,4 ,5 ]
机构
[1] Mediprobe Res Inc, 645 Windermere Rd, London, ON N5X 2P1, Canada
[2] Univ Toronto, Sch Med, Div Dermatol, Dept Med, Toronto, ON, Canada
[3] Sunnybrook Hlth Sci Ctr, Div Dermatol, Toronto, ON, Canada
[4] Cardiff Univ, Div Infect & Immun, Sch Med, Cardiff, S Glam, Wales
[5] Womens Coll Hosp, Div Dermatol, Toronto, ON, Canada
关键词
Diagnosis; treatment; onychomycosis; TOENAIL ONYCHOMYCOSIS; TRICHOPHYTON-RUBRUM; NAIL LACQUER; EPIDEMIOLOGY; DERMATOPHYTE; PREVALENCE; IDENTIFICATION; EFFICACY; PCR; EFINACONAZOLE;
D O I
10.1080/14787210.2018.1544891
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Onychomycosis is a chronic fungal infection of the nail bed, matrix or plate. It accounts for roughly 50% of all nail disease. As the prevalence of onychomycosis is increasing, a critical review of diagnostic techniques and treatment options is required. Areas covered: This review discusses the current diagnostic techniques associated with diagnosing onychomycosis, such as microscopy, culture, periodic acid Schiff stain (PAS) and polymerase chain reaction (PCR). Oral and topical therapies are also discussed, as well as, the utility of device-based treatments and combination therapy. Expert commentary: Culture for the diagnosis of onychomycosis is the gold standard; however, PCR is more sensitive and should be considered. In general, topical treatments are recommended for mild to moderate disease and oral treatments should be considered for moderate to severe disease. Combination therapy and device-based treatments may enhance cure rates, further study is required.
引用
收藏
页码:929 / 938
页数:10
相关论文
共 85 条
[1]  
Abastabar M, 2018, ANTIMICROB AGENTS CH
[2]  
Anacor Pharmaceuticals Inc, 2014, FDA APPR AN PHARM LS
[3]  
[Anonymous], 2018, SPORANOX ITR CAPS
[4]  
[Anonymous], 2017, LAMISIL TERB HYDR TA
[5]  
[Anonymous], 2016, FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme
[6]  
[Anonymous], TERB
[7]   Prevalence of Candida tropicalis and Candida krusei in onychomycosis in Joao Pessoa, Paraiba, Brazil from 1999 to 2010 [J].
Arrua, Juliana M. M. ;
Rodrigues, Luis A. S. ;
Pereira, Fillipe O. ;
Lima, Edeltrudes O. .
ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS, 2015, 87 (03) :1819-1822
[8]   An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis [J].
Baran, R. ;
Tosti, A. ;
Hartmane, I. ;
Altmeyer, P. ;
Hercogova, J. ;
Koudelkova, V. ;
Ruzicka, T. ;
Combemale, P. ;
Mikazans, I. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (07) :773-781
[9]   Evaluation of a single-tube real-time PCR for detection and identification of 11 dermatophyte species in clinical material [J].
Bergmans, A. M. C. ;
van der Ent, M. ;
Klaassen, A. ;
Bohm, N. ;
Andriesse, G. I. ;
Wintermans, R. G. F. .
CLINICAL MICROBIOLOGY AND INFECTION, 2010, 16 (06) :704-710
[10]   Fractional carbon-dioxide (CO2) laser-assisted topical therapy for the treatment of onychomycosis [J].
Bhatta, Anil Kumar ;
Keyal, Uma ;
Huang, Xin ;
Zhao, Jing Jun .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) :916-923